REG - Aptamer Group PLC - Aptamer Progresses Partnership with Unilever

AptamerAnnouncement

11/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240311:nRSK2483Ga&default-theme=true

RNS Number : 2483G  Aptamer Group PLC  11 March 2024

11 March 2024

 

Aptamer Group plc

 

("Aptamer" or the "Company")

 

      Aptamer Group progresses partnership with Unilever plc ("Unilever")

-  Successful Optimer(®) development for fast-moving consumer goods

-  The partnership has advanced to warrant the patenting of the new binders

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, today announces the
successful progression of its long-standing development partnership with
Unilever for identification of Optimers capable of supporting the development
of novel fast moving consumer goods ("FMCG") applications.

 

Following formation of a partnership with Unilever in FY2023, Aptamer has
successfully developed the required Optimers and demonstrated their
performance through in-house assays. After being shipped to Unilever, the
Optimers delivered highly positive and reproducible results in their
laboratories, indicating their potential for use in downstream products. In
parallel, Aptamer has streamlined the Optimers to improve their function and
manufacturability and is working to transfer these to Unilever for further
evaluation.

 

Based on the successful progress of this scientific work, Aptamer and Unilever
are now drafting patent applications to protect these developments and
downstream commercial applications.

 

Steve Hull, Chairman of Aptamer Group, said: "We are delighted to support our
partners at Unilever with Optimer technology that is providing novel solutions
in multiple areas, now including fast-moving consumer goods. Over the past two
years, we have worked closely with the team at Unilever, to develop successful
binders and are pleased to see the promising results the binders are
delivering in their laboratories, further validating our technology and
leadership position in the affinity ligand market. With such strong results
and the continued progression of this partnership, we are pleased to begin
patenting these binders and allow the next stage of advances. I look forward
to updating you on this project as it develops."

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over US$170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCURUKRSSUOAAR